MoneyTalks: Prescient set for ‘big pay day’; Aerometrex to grab ‘blue ocean’ AI opportunity
Pitt Street Research has sent us its thesis on biotech stock, Prescient Therapeutics (ASX:PTX), with a valuation range...
Pitt Street Research has sent us its thesis on biotech stock, Prescient Therapeutics (ASX:PTX), with a valuation range...
It’s a wrap for the September quarter. Here are some of the latest highlights from...
Clinical stage oncology company Prescient Therapeutics will showcase the results of its Phase 1b study in...
Prescient Therapeutics is on a mission to improve outcomes for cancer patients, and it is...
It’s the quarterly season again as the ASX market announcements page becomes increasingly flooded with...
Stockhead’s resident health and biotech expert Tim Boreham is putting down the microscope and picking up...
It’s the quarterly season again as the ASX market announcements page becomes increasingly flooded with...
Stockhead’s resident health and biotech expert Tim Boreham is putting down the microscope and picking up...
Prescient Therapeutics is hoping to follow in the footsteps of Neuren Pharmaceuticals after positive results...
Telix Pharma (ASX:TLX) announced the US FDA has approved a supplementary New Drug Application (sNDA) for Illuccix,...
This investor centre was built by Reach Markets
©2022 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.